A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms HAVEN 5
- Sponsors Roche
- 10 Sep 2019 Planned number of patients changed from 70 to 85.
- 10 Sep 2019 Planned End Date changed from 28 Jan 2020 to 22 Sep 2021.
- 10 Sep 2019 Planned primary completion date changed from 3 Sep 2019 to 17 Dec 2020.